Open Access

Clinical and imaging features of subependymal giant cell astrocytoma: report of 20 cases

Contributed equally
Chinese Neurosurgical Journal20173:14

https://doi.org/10.1186/s41016-017-0077-4

Received: 16 May 2016

Accepted: 11 February 2017

Published: 5 May 2017

Abstract

Background

Subependymal giant cell astrocytoma (SEGA) is a clinically benign brain tumor associated with tuberous sclerosis complex (TSC). There are still controversies on early diagnosis of the tumor.

Methods

CT and MR imaging of 20 patients with pathologically confirmed SEGA were retrospectively reviewed. Two radiologists evaluated the location, shape, size, number, edge, cerebral edema, homogeneous or heterogeneous appearance, attenuation and signal intensity, degree of enhancement and calcification of lesions. Their prognoses were based on clinical observations.

Results

SEGA showed similar features in imaging: an extra-axial, well-circumscribed, periventricular mass, isodense or slightly hyperdense on CT, hypointensity on T1-weighted imaging and isointensity to hyperintensity on T2-weighted imaging. The mass enhanced markedly and heterogeneously after the administration of contrast agent. Subependymal nodules were demonstrated in 5 cases. Remarkably, 17 patients (85%) showed ventricular dilatation and 14 patients (70%) showed calcification in CT and MR imaging. Moreover, perifocal edema was not significantly near the masses. Four cases are associated with tuberous sclerosis complex (TSC).

Conclusions

Although there are no pathognomonic imaging findings for SEGA, the following clinical and imaging features might be helpful for the diagnosis, such as the initial age of first or second decade, typical location in the periventricular regions adjacent to the foramen of Monro, hydrocephalus accompanied with raised intracranial pressure, TSC and marked heterogeneous enhancement.

Keywords

Subependymal giant cell astrocytoma Tuberous sclerosis complex Central nervous system Computed tomography Magnetic resonance imaging

Background

Subependymal giant cell astrocytoma (SEGA) is a World Health Organization (WHO) Grade I tumor that typically occurs in the lateral ventricle near the foramen of Monro and rarely in the third ventricle [1]. Nevertheless, their outcome may be poor due to obstructive hydrocephalus or intratumoral hemorrhage [2]. The association of this tumor with tuberous sclerosis complex (TSC) is well known; however, its histogenesis is poorly understood. Its pure astrocytic nature has been doubted and several recent reports demonstrate it is mixed, glio-neuronal nature [3]. The purpose of this study was to delineate the basic clinical and imaging features of SEGA in a series of 20 histologically verified consecutive patients treated at our institution and to analyze previously reported cases.

Methods

Patient data

We reviewed cross-referenced records from Sep. 2002 to Dec. 2010 in the departments of radiology, neurosurgery and pathology of our hospital and identified 20 patients with pathologically confirmed SEGA, including 11 males (55%) and 9 females (45%). Computed tomography (CT) images were available in 14 patients and MRI images were available in all the 20 patients. All cases underwent craniotomy.

CT and MRI technique

CT scanning was performed for 14 patients using cranial CT scanner (LightSpeed, GE Medical Systems, US or Somatom Plus, Siemens, Germany). Eleven patients had non-enhanced CT images while three patients (patient 7, 8 and 15) had both non-enhanced CT and contrast material–enhanced CT images. They received 1.5 ml/kg of iohexol (Omnipaque 300; Amersham, Shanghai, China) before they underwent CT scans.

For each patient, non-enhanced MRI and contrast material–enhanced MRI scanning was performed using 1.5-T MRI scanner (Signa, GE Medical Systems, US) equipped with the standard head coil with a 240 × 240 mm field of view.

Findings were recorded by consensus. We investigated CT and MR imaging characteristics, with emphasis on the location, size, internal content, margin of the lesion, pattern of enhancement and change of the adjacent structures. The size of the lesion was measured at its greatest diameter. As for the internal content, the lesions were divided into solid and cystic. At non-enhanced CT and MRI, attenuation (signal intensity) was classified as hypodense (hypointensity), isodense (isointensity), or hyperdense (hyperintensity) compared with the adjacent cerebral parenchyma. And after contrast-enhancement, degree of CT enhancement was classified as no enhancement, mild (10-20Hu), moderate (20–50 Hu), or marked (>50 Hu) while degree of MRI enhancement was classified as no enhancement, mild (slightly higher than that of cerebral parenchyma), moderate (lower than that of dura), or marked (equal to that of dura).

Survival analysis

Survival analysis was done by SPSS software for Windows (version 16.0). The Kaplan–Meier method was used to measured Recurrence-free survival (RFS). And the assessments of Kaplan–Meier plots were tested using log rank. P values <0.05 were considered to be statistically significant.

Results

Demographics

This series included 11 males and nine females, with ages ranging from 5 to 32 years (mean age, 16.4 years, fifteen at <18).

Clinical characters

The most common symptom was increased intracranial pressure (n = 16, 80%) in accompany with headache (n = 16, 80%), vomiting (n = 5, 25%) and visual disorder (n = 3, 15%), and other presentations included paroxysmal epilepsy (n = 9, 45%) and facial angiofibromas (n = 4, 20%). Among 9 patients with epilepsy, three (patient 5, 9 and 12) were also associated with mental retardation. The duration from the appearance of the initial symptom(s) to diagnosis varied from 3 days to 10 years. The appearance of epilepsy was in smaller tumors in early stage. Headache and visual disorder was in bigger tumors in later stage. Four cases are associated with tuberous sclerosis complex (TSC) in pathology. The data of clinical characters of the 20 patients were recorded in Table 1.
Table 1

Grade, age, symptom, location and follow-up of the investigated SEGAs in 20 eligible subjects

Subject no

Sex

Age

Symptom

Diameter (cm)

Tumor location

associated with tuberous sclerosis complex

treatment

Follow-up time (months)/Symptoms

Survival status

1

M

7

Headache

3

Right lateral ventricle

No

Total removal

24 / Non

Non-recurrence

2

F

16

Headache

4

Right lateral ventricle

No

Total removal

13 / Non

Non-recurrence

3

F

26

Headache, Epilepsy

3

Right lateral ventricle

No

Total removal

13 / Epilepsy

Non-recurrence

4

M

17

Headache, vomiting

6

Left lateral ventricle

No

Total removal

16 / hemiplegia

Non-recurrence

5

F

5

Epilepsy, mental retardation

4

Left lateral ventricle

Yes

Total removal

35 / Epilepsy, mental retardation

Non-recurrence

6

M

13

Headache, Epilepsy

3

Right lateral ventricle

No

Total removal

26 / Non

Non-recurrence

7

F

30

Headache, vomiting, visual disorder

7

Right lateral ventricle

No

Subtotal removal & radiotherapy

25 / Headache, visual disorder

Recurrence

8

M

16

Headache, Epilepsy

3

Right lateral ventricle

No

Total removal

27 / Non

Non-recurrence

9

F

6

Epilepsy, mental retardation

3

Left lateral ventricle

Yes

Total removal

22 / Epilepsy, mental retardation

Non-recurrence

10

F

12

Headache, vomiting

4

Left lateral ventricle

No

Total removal

8 / Non

Non-recurrence

11

M

16

Epilepsy,

2

Right lateral ventricle

No

Total removal

15 / Non

Non-recurrence

12

M

6

Headache, Epilepsy, mental retardation

4

Left lateral ventricles

Yes

Total removal

18 / Epilepsy, mental retardation

Non-recurrence

13

F

13

Headache, vomiting, visual disorder

10

Left lateral ventricle

No

Partial removal & radiotherapy

26 /Headache, visual disorder

Recurrence

14

F

26

Headache, Epilepsy

3

Both lateral ventricle

No

Total removal

13 / Epilepsy

Non-recurrence

15

M

16

Epilepsy,

2

Right lateral ventricle

No

Total removal

15 / Non

Non-recurrence

16

F

22

Headache

4

Right lateral ventricle

No

Total removal

17 / Non

Non-recurrence

17

M

15

Headache, vomiting, visual disorder

7

Right lateral ventricle

Yes

Subtotal removal & radiotherapy

12 / visual disorder

Non-recurrence

18

M

32

Headache

2

Third ventricle

No

Total removal

23/ Headache

Recurrence

19

M

17

Headache

5

Right lateral ventricle

No

Total removal

32 / Non

Non-recurrence

20

M

17

Headache

3

Left lateral ventricle

No

Total removal

25 / Non

Non-recurrence

Lesion locations

The most common location was lateral ventricle (n = 19, 95%). Among the 19 cases, one patient with two lesions located in both lateral ventricles. The remaining one was predominantly in the third ventricle. The lesion size ranged from 2 cm to 10 cm, with a mean of 4.1 cm. The margins of all masses were well- defined with a lobulate contour.

Radiological findings

As shown in Fig. 1, similar imaging features of SEGA were an extra-axial, typically around the region of Monro foramen, well-circumscribed mass. CT imaging data were available in 14 cases. CT scan showed isodense (n = 7) or slightly hyperdense (n = 7) masses with markedly heterogeneous enhancement after administration of the contrast agent, and cystic degeneration within lesions was noted in 3 patients (patient 9, 13 and 17). In addition, amorphous calcification was seen in all the 14 cases, and 5 associated with small tubers on either side of the ventricular wall. MRI imaging data were available in all cases. Most of the tumors were hypointense on T1WI and isointense to hyperintense on T2WI. Remarkably, ten patients (case 3–6, 8, 10, 11, 14–16) showed strong hypointensity, five patients (2, 9, 12, 13 and 18) showed isointensity, while the remaining 5 patients (1, 7, 17, 19 and 20) showed hypointensity within isointensity on T1-weighted or fluid attenuated inversion recovery (FLAIR) images. On T2-weighted or FLAIR images, 13 patients (case 2, 4, 6, 9–13, 15–18 and 20) showed strong hyperintensity; hypointensity (case 3) and isointensity (case 5) were seen in one case each; the remaining 5 patients (1, 7, 8, 14 and 19) showed hyperintensity within hypointensity. All tumors demonstrated moderate to strongly heterogenous enhancement after administration of gadolinium, and marked peritumoral edema was not obvious in our study. Hyperintensity and hypointensity on diffusion-weighted imaging (DWI) were observed in 2 cases each (case 5, 6, 10 and 19). Seventeen patients (case 1–8, 10, 12–14 and 16–20) involved ventricular dilatation.
Fig. 1

a Nonenhanced CT image shows slightly hyperdense lesion with calcification at the right lateral ventricle adjacent to the foramen of Monro. Axial T1-weighted (b) MR images show the mass is well-defined with the ventricular dilatation, and the mass enhances strongly and homogeneously after the administration of Gd-based contrast agent

Follow-up

In this study, total macroscopic removal was achieved in 17 patients (85%), subtotal removal in 2 patients (10%), and partial removal in one patient (5%). The follow-up ranged from 8 to 35 months. Most of the patients have exhibited similar physical and mental conditions to preoperative. There has been evidence of recurrences in 3 cases (15%). The details of follow-up were recorded in Table 1.

To compare the recurrence-free survival (RFS) for patients with bigger tumors (diameter > = 4cm) versus those with smaller tumors (diameter < 4cm). RFS was determined using the Kaplan–Meier method and assessments of Kaplan–Meier plots were tested using log rank. As shown in Fig. 2, Kaplan–Meier plots and log rank of SEGA shows that there was no significant difference between patients with bigger tumors and those with smaller tumors (P = 0.059). This may be due to too few cases.
Fig. 2

Kaplan–Meier plots and log rank of SEGA shows that there was no significant difference between patients with bigger tumors (diameter > = 4cm) and those with smaller tumors (diameter < 4cm) (P = 0.059)

Discussion

Clinical presentation

SEGA is a WHO Grade I tumor that often occurs in the lateral ventricle near the foramen of Monro and rarely in the third ventricle, the fourth ventricle and pineal region [13]. However, the outcome of SEGA may be poor due to obstructive hydrocephalus or intratumoral hemorrhage [4]. Tuberous sclerosis complex has an association with sudden death. Sudden death may be due to epilepsy, cardiac arrhythmia, and intra-tumoral hemorrhage [5, 6]. Some authors reported that SEGA has been no evidence of any recurrence even after subtotal removal. However, some other authors considered that residual lesions tended to develop [3, 7].

SEGA accounts for 1.5% of all pediatric brain tumors [8]. In our study, the mean initial age was 16.4 years (range: 5–32years), and 15 patients were less than 18 years upon initial diagnosis, indicating that SEGA tended to occur in young patients. This was similar to the previously reported cases where the age distribution was in the first two decades of life, with the highest frequency in those 5–13 years old [911]. The male to female ratio in our series was 11: 9, which did not show obvious sex bias. However, in the group below 18 years, the male: female was 2:1, which showed a prominent male predilection. One of the previous reports described a slight male predominance, which was the same with our result [12]. These demographic discrepancies between the studies were probably caused by a selection bias because of the small number of cases.

It was generally believed that SEGA had a tendency to arise within periventricular regions often adjacent to the foramen of Monro [13]. In our study, the lateral ventricular location was much more frequent (19/20) than the other ventricular location. The remaining one SEGA was in the third ventricle. This distribution pattern was similar to conventional SEGA [1]. Rarely, parenchymal locations have been described in the brain (Basal ganglia and frontal lobe) [8, 14]. Depending on the location of tumors, the most common symptom was increased intracranial pressure. Although SEGA was thought slowly growing, it always deteriorated due to elevated intracranial pressure [15].

Associations with tuberous sclerosis complex

Other symptom, such as abnormal dermatosis was reported to be associated with TSC. When the clinical sign of Tuberous sclerosis (TS) was obvious, an early diagnosis of SEGA was common. Nevertheless, in cases with no evidence of TS, diagnosis and treatment of SEGA in adult seems to be a challenge. A rare case of an intratumoral and a small intraventricular hemorrhage complicating a SEGA without any signs of TS was reported [16]. Thus, a high index of suspicion and urgent treatment should be also required, when SEGA outside the clinical setting of the TS complex and with some urgent presentations. TSC was an autosomal disease and about 60% cases arise as spontaneous mutations as one feature for SEGA. None of our patients had positive family history for TSC. Before the advances in neuroimaging, the diagnosis of TSC was based on clinical manifestation and histopathological findings (Fig. 3). The classic clinical triad of Vogt included facial angiofibroma, mental retardation, and seizures [17].
Fig. 3

Histopathological image shows that there are numerous giant cells with eccentric nuclei and tumor cells line up around the blood vessel. (original magnification, ×400)

Earnest L et al.’s study has been shown that 45% of TSC-affected patients had normal intelligence, 29% had features of “Vogt’s triad” and 6% hadn’t any of three features [18]. In our analysis, only one patient presented with classical Vogt’s triad (case 12). TSC was a disorder of cellular migration and differentiation involving all of the germinal layers. It was manifested by hamartomas formed in skin, CNS and viscera. Facial angiofibromas were presented in approximately 85% of older children and adolescents. Multiple peri/subungual fibromas, pathognomonic of were seen in 15–20% of cases [19], as seen in our cases that all these 4 patients with facial angiofibroma were over 3 years old.

TSC has a high incidence for mental retardation, especially when associated with seizures in children. The earlier the seizures occured, the poorer was the intellectual outcome of the patient [19]. In present series, 2 patients with epilepsy showed poor intellectual development at the age of 4 months and 3 years respectively. Therefore, it seemed some correlations between seizure and intellection.

Imaging features

The major neuroradiological lesions are tubers, SEN and SEGA. Nodules and tumors were both located at the subependymal region. A pathogenetic link between SEN and SEGA has been confirmed. Several studies have showed that there was a continuum from SEN to SEGA. The risk factors of the SEN transformed into a tumor primarily included a diameter above 5 mm, calcification and enhancement after gadolinium administration. Moreover, some studies have showed that all SENs were clonal, had the capacity to proliferate, and behaved as true neoplasms [9]. How to distinguish a tumor from SEN is still difficult especially at an earlier stage when the lesion is very small [20]. There were many studies about signal intensity or dense and contrast-enhancing characteristics suggesting correlations between SEN and SEGA [20]. The uniquely detectable difference between SEN and SEGA was the tendency of the latter lesion to enlarge and to obviously enhance with contrast administration in both CT and MRI image [21]. Cortical tubers were better diagnosed on MRI imaging than on CT scan, and they were low signal intensity in T1-weighted imaging and high signal intensity in T2-weighted imaging [20]. However, some authors suggested that signal intensity and contrast enhancement were not useful in detecting the difference between SEN and SEGA, because they found that some SENs also had slight enhancement on radiological imaging [22]. Therefore, the clinical criteria were more important than radiological images in diagnosis. If patients had hydrocephalus or high intracranial pressure, the perimonro lesion could be diagnosed as a tumor [6]. When a lesion near monro was not big enough to diagnose as a tumor, serial follow-up was essential [20]. With the growth of lesion on serial MRI image, the diagnosis of tumor could be made easily. We agreed with the criteria put forward by Cuccia at 2003 which included presence of hydrocephalus, interval increase in tumor size, new focal neurological deficit attributable to tumor, and/or symptoms of intracranial pressure [20].

SEGA appeared to arise from SEN on serial imaging, which was present in 88–95% of patients with TSC [13]. The nodule would grow up even with the treatment of gamma knife after 2 years follow-up [6]. Moreover, the lesion seemed more like a tumor because of its obvious enhancement and absence of calcification.

The common sites of SEGA were cerebral ventricles, including third ventricle, fourth ventricle and lateral ventricle. Only a few cases have been reported of SEGA with intra-axial extension in the literature. To our knowledge, only three cases were reported located at cerebral hemisphere [10, 22, 23].

On CT scan, they were well circumscribed, isodense or hyperdense, and were obviously and homogeneously enhanced after injection of contrast medium; on MRI finding, tumors were isointense, hypointense or hypointense within isointense on T1-weighted or FLAIR images, and hyperintense, isointense or hypointense on T2-weighted image or FLAIR images. Being moderate to strongly heterogenous enhancement could be seen on all of the MRI images. Moreover, frequent calcification and ventricular dilatation could be noted.

In differentiating lateral ventricular tumours, the CT density and morphology characteristics were non-specific, and MR signal intensity patterns, which varied from case to case, were also unhelpful in predicting tumour histology. Currently, data available in the literature showed that exact diagnosis of ventricular neoplasms (neurocytoma, ependymoma, subependymoma, SEGA) was hardly possible on the CT and MRI images since nearly every variation of imaging characteristics (hypo- or hyperintense, contrast enhancement, cyst, etc.) may be present or entirely absent in a single case [12]. Ventricular ependymomas were mostly hyperdense with pronounced contrast uptake. On the contrary, subependymomas were hypodense, mostly without enhancement, but occasionally slight or moderate enhancement was noted, and SEGA also displayed hypodense, rarely hyperdense or mixed imaging characteristics and always in significant degree of contrast enhancement [12]. In accordance with previous reports, all showed hypo- or mixed density, but mostly slight to moderate enhancement. Ependymomas, anaplastic astrocytomas and glioblastomas followed the characteristics of the similar extraventricular ones [21]. The imaging features of ventricular neoplasms were non-specific and usually the diagnosis was made after taking the patient’s clinical condition, age and the location of tumors into consideration. We supposed that the diversity of CT or MR image might due to the different histologic contents of the tumor, such as calcification, necrosis or hemorrhage. We thought that more SEGA cases are needed to further evaluate this problem.

Overall, although the appearance of the tumors on CT or MR imaging scans in our patients was initially indistinguishable from that of other lateral ventricle gliomas and central neurocytomas, clinical features including presence in the first or second decade of life, typical location in the periventricular regions adjacent to the foramen of Monro, hydrocephalus in company with raised intracranial pressure and TSC might be a characteristic finding for SEGA.

Conclusions

Although there are no pathognomonic imaging findings for SEGA, some clinical and imaging features such as presence in the first or second decade, typical location in the periventricular regions adjacent to the foramen of Monro, hydrocephalus in company with raised intracranial pressure, TSC and marked heterogeneous enhancement might be helpful for the diagnosis.

Abbreviations

CT: 

Computed tomography

DWI: 

Diffusion-weighted imaging

FLAIR: 

Fluid-attenuated inversion recovery

MRI: 

Magnetic resonance imaging

SE: 

Subependymomas

SEGA: 

Subependymal giant cell astrocytoma

SEN: 

Subependymal nodules

TS: 

Tuberous sclerosis

TSC: 

Tuberous sclerosis complex

Declarations

Acknowledgements

We thank Professor Liang-Fu Zhou, Professor Ying Mao, Professor Xiao-Ming Che, Professor Rong Zhang, Professor Wei Zhu and Professor Zhi-Yong Qin for providing patients’ information. We thank Professor Lin Zhu for reading the manuscript and editing it. We also thank Professor Bin Li for expert opinions during the development of this manuscript. In our study, there is not conflict of interest.

Funding

We have no source of funding.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

GHM, PZ and XXL carried out the studies, participated in collecting data, and drafted the manuscript. MS and GHM performed the statistical analysis and participated in its design. All authors read and approved the final manuscript.

Competing interests

The authors report no potential conflicts of interest concerning the materials or methods used in this study or the findings presented.

Consent for publication

Written informed consent was obtained from patient (patient was over 16 year’s old) or his/her patients (patient was under 16 year’s old).

Ethics approval and consent to participate

This retrospective study was undertaken at the Huashan Hospital (Shanghai, China) with approval from the Huashan Institutional Review Board.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neurosurgery, Huashan Hospital, Fudan University
(2)
Department of Cyberknife, Huashan Hospital, Fudan University

References

  1. Buccoliero AM, Franchi A, Castiglione F, Gheri CF, Mussa F, Giordano F, Genitori L, Taddei GL. Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology. 2009;29:25–30.View ArticlePubMedGoogle Scholar
  2. Dashti SR, Robinson S, Rodgers M, Cohen AR. Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. J Neurosurg. 2005;102:322–5.PubMedGoogle Scholar
  3. Nishio S, Morioka T, Suzuki S, Kira R, Mihara F, Fukui M. Subependymal giant cell astrocytoma: clinical and neuroimaging features of four cases. J Clin Neurosci. 2001;8:31–4.View ArticlePubMedGoogle Scholar
  4. Lopes MB, Altermatt HJ, Scheithauer BW, Shepherd CW, VandenBerg SR. Immunohistochemical characterization of subependymal giant cell astrocytomas. Acta Neuropathol. 1996;91:368–75.View ArticlePubMedGoogle Scholar
  5. Prahlow JA, Teot LA, Lantz PE, Stanton CA. Sudden death in epilepsy due to an isolated subependymal giant cell astrocytoma of the septum pellucidum. Am J Forensic Med Pathol. 1995;16:30–7.View ArticlePubMedGoogle Scholar
  6. Byard RW, Blumbergs PC, James RA. Mechanisms of unexpected death in tuberous sclerosis. J Forensic Sci. 2003;48:172–6.View ArticlePubMedGoogle Scholar
  7. DeRibaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, Delalande O. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60:83–9.View ArticleGoogle Scholar
  8. Isik U, Dincer A, Sav A, Ozek MM. Basal ganglia location of subependymal giant cell astrocytomas in two infants. Pediatr Neurol. 2010;42:157–9.View ArticlePubMedGoogle Scholar
  9. Utsuki S, Oka H, Kijima C, Yasui Y, Fujii K, Kawano N, Yagishita S. Subependymal giant cell astrocytoma with oncocytic change. Brain Tumor Pathol. 2011;28:53–7.View ArticlePubMedGoogle Scholar
  10. Jiang T, Jia G, Ma Z, Luo S, Zhang Y. The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst. 2011;27:55–62.View ArticlePubMedGoogle Scholar
  11. Sharma MC, Ralte AM, Gaekwad S, Santosh V, Shankar SK, Sarkar C. Subependymal giant cell astrocytoma--a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res. 2004;10:219–24.View ArticlePubMedGoogle Scholar
  12. Osztie E, Hanzely Z, Afra D. Lateral ventricle gliomas and central neurocytomas in adults diagnosis and perspectives. Eur J Radiol. 2009;69:67–73.View ArticlePubMedGoogle Scholar
  13. Raju GP, Urion DK, Sahin M. Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol. 2007;36:128–31.View ArticlePubMedGoogle Scholar
  14. Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C. Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry. 1999;66:370–5.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Telfeian AE, Judkins A, Younkin D, Pollock AN, Crino P. Subependymal giant cell astrocytoma with cranial and spinal metastases in a patient with tuberous sclerosis. Case Report J Neurosurg. 2004;100:498–500.PubMedGoogle Scholar
  16. Stavrinou P, Spiliotopoulos A, Patsalas I, Balogiannis I, Karkavelas G, Polyzoidis K, Selviaridis P. Subependymal giant cell astrocytoma with intratumoral hemorrhage in the absence of tuberous sclerosis. J Clin Neurosci. 2008;15:704–6.View ArticlePubMedGoogle Scholar
  17. Roach ES, Smith M, Huttenlocher P, Bhat M, Alcorn D, Hawley L. Diagnostic criteria: tuberous sclerosis complex. Report of the Diagnostic Criteria Committee of the National Tuberous Sclerosis Association. J Child Neurol. 1992;7:221–4.View ArticlePubMedGoogle Scholar
  18. Earnest L, Byrne P, Califano J. Massive facial angiofibroma in a patient with tuberous sclerosis. Otolaryngol Head Neck Surg. 2003;128:151–3.View ArticlePubMedGoogle Scholar
  19. Kumar R, Singh V. Subependymal giant cell astrocytoma: a report of five cases. Neurosurg Rev. 2004;27:274–80.PubMedGoogle Scholar
  20. Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 2003;19:232–43.PubMedGoogle Scholar
  21. Braffman BH, Bilaniuk LT, Naidich TP, Altman NR, Post MJ, Quencer RM, Zimmerman RA, Brody BA. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology. 1992;183:227–38.View ArticlePubMedGoogle Scholar
  22. Hon SF, Wong GK, Zhu XL, Ng HK, Sin NC, Poon WS. Surgical treatment of a neonate with refractory seizures secondary to congenital giant cell astrocytoma: case report and literature review. Hong Kong Med J. 2006;12:222–4.PubMedGoogle Scholar
  23. Oikawa S, Sakamoto K, Kobayashi N. A neonatal huge subependymal giant cell astrocytoma: case report. Neurosurgery. 1994;35:748–50.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement